About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Tg(TPO-cre/ERT2)1139Tyj
transgene insertion 1139, Tyler Jacks
MGI:5565332
Summary 4 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Braftm1Mmcm/Braf+
Tg(TPO-cre/ERT2)1139Tyj/0 		involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac MGI:5897855
cn2
 		Braftm1Mmcm/Braf+
Trp53tm3.1Tyj/Trp53+
Tg(TPO-cre/ERT2)1139Tyj/0 		involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac MGI:5897857
cn3
 		Braftm1Mmcm/Braf+
Trp53tm1Brn/Trp53tm3.1Tyj
Tg(TPO-cre/ERT2)1139Tyj/0 		involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac MGI:5897858
cn4
 		Braftm1Mmcm/Braf+
Tg(TPO-cre/ERT2)1139Tyj/0
Trp53tm1Brn/Trp53tm1Brn 		involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac MGI:5897859


Genotype
MGI:5897855
cn1
Allelic
Composition		 Braftm1Mmcm/Braf+
Tg(TPO-cre/ERT2)1139Tyj/0
Genetic
Background		 involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Mmcm mutation (3 available); any Braf mutation (60 available)
Tg(TPO-cre/ERT2)1139Tyj mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
endocrine/exocrine glands
increased thyroid carcinoma incidence ( J:208854 )
• mice administered tamoxifen develop papillary thyroid carcinomas
• tumors show both papillary growth morphology and nuclear features of papillary thyroid carcinoma
• even with very long latency, extrathyroidal invasion is not seen and cervical lymph node metastases are not seen

neoplasm
increased thyroid carcinoma incidence ( J:208854 )
• mice administered tamoxifen develop papillary thyroid carcinomas
• tumors show both papillary growth morphology and nuclear features of papillary thyroid carcinoma
• even with very long latency, extrathyroidal invasion is not seen and cervical lymph node metastases are not seen

respiratory system
respiratory failure ( J:208854 )
• tamoxifen treated mice generally succumb to respiratory compromise due to tracheal compression by large noninvasive tumors




Genotype
MGI:5897857
cn2
Allelic
Composition		 Braftm1Mmcm/Braf+
Trp53tm3.1Tyj/Trp53+
Tg(TPO-cre/ERT2)1139Tyj/0
Genetic
Background		 involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Mmcm mutation (3 available); any Braf mutation (60 available)
Tg(TPO-cre/ERT2)1139Tyj mutation (1 available)
Trp53tm3.1Tyj mutation (2 available); any Trp53 mutation (240 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:208854 )
• tamoxifen treated mice exhibit shortened survival

endocrine/exocrine glands
increased thyroid carcinoma incidence ( J:208854 )
• tamoxifen treated mice develop large papillary thyroid carcinoma that exhibit features associated with aggressive behavior including solid growth, tall cell morphology, focal necrosis, and hobnail features
• about 50% of mice with papillary thyroid carcinoma acquire poorly differentiated thyroid carcinoma or undifferentiated anaplastic thyroid carcinoma

neoplasm
increased thyroid carcinoma incidence ( J:208854 )
• tamoxifen treated mice develop large papillary thyroid carcinoma that exhibit features associated with aggressive behavior including solid growth, tall cell morphology, focal necrosis, and hobnail features
• about 50% of mice with papillary thyroid carcinoma acquire poorly differentiated thyroid carcinoma or undifferentiated anaplastic thyroid carcinoma




Genotype
MGI:5897858
cn3
Allelic
Composition		 Braftm1Mmcm/Braf+
Trp53tm1Brn/Trp53tm3.1Tyj
Tg(TPO-cre/ERT2)1139Tyj/0
Genetic
Background		 involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Mmcm mutation (3 available); any Braf mutation (60 available)
Tg(TPO-cre/ERT2)1139Tyj mutation (1 available)
Trp53tm1Brn mutation (18 available); any Trp53 mutation (240 available)
Trp53tm3.1Tyj mutation (2 available); any Trp53 mutation (240 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
endocrine/exocrine glands
increased thyroid carcinoma incidence ( J:208854 )
• tamoxifen treated mice exhibit accelerated progression to poorly differentiated thyroid carcinoma and overt undifferentiated anaplastic thyroid carcinoma with highly pleomorphic, atypical cells with evidence of necrosis

neoplasm
increased thyroid carcinoma incidence ( J:208854 )
• tamoxifen treated mice exhibit accelerated progression to poorly differentiated thyroid carcinoma and overt undifferentiated anaplastic thyroid carcinoma with highly pleomorphic, atypical cells with evidence of necrosis




Genotype
MGI:5897859
cn4
Allelic
Composition		 Braftm1Mmcm/Braf+
Tg(TPO-cre/ERT2)1139Tyj/0
Trp53tm1Brn/Trp53tm1Brn
Genetic
Background		 involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Mmcm mutation (3 available); any Braf mutation (60 available)
Tg(TPO-cre/ERT2)1139Tyj mutation (1 available)
Trp53tm1Brn mutation (18 available); any Trp53 mutation (240 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
decreased tumor-free survival time ( J:208854 )
• median survival of about 6 months following tumor induction with tamoxifen
• tumor induced mice treated with the BRAF inhibitor PLX4720 show improved survival
• tumor induced mice treated with both the BRAF inhibitor PLX4720 and the selective MEK inhibitor PD0325901show prolonged survival

neoplasm
increased thyroid carcinoma incidence ( J:208854 )
• tamoxifen treated mice exhibit accelerated progression from papillary thyroid carcinoma to poorly differentiated thyroid carcinoma and overt undifferentiated anaplastic thyroid carcinoma with highly pleomorphic, atypical cells with evidence of necrosis
• carcinoma in tamoxifen treated mice shows tracheal invasion and extrathyroidal extension
• marker analysis indicates that anaplastic thyroid carcinoma in tamoxifen treated mice originates from thyroid epithelium
• tumors from tamoxifen treated mice exhibit very slow initial growth upon induction but rapid tumor growth after a variable latency
• mice supplemented with L-thyroxine immediately following tamoxifen administration show suppressed TSH levels and develop anaplastic thyroid carcinoma with a similar latency as unsupplemented controls
• anaplastic thyroid carcinomas exhibit a gene expression profile of high-grade, undifferentiated carcinomas
• tumor induced mice treated with the BRAF inhibitor PLX4720 show improved survival and a decrease in contralateral papillary thyroid carcinomas, however no decrease in anaplastic thyroid carcinoma size is seen and tumors even grow larger
• tumor induced mice treated with both the BRAF inhibitor PLX4720 and the selective MEK inhibitor PD0325901 show complete regression of tumors and prolonged survival
increased metastatic potential ( J:208854 )
• 19% of tamoxifen treated mice exhibit lung metastases
• however, region lymph node metastases are not seen

endocrine/exocrine glands
increased thyroid carcinoma incidence ( J:208854 )
• tamoxifen treated mice exhibit accelerated progression from papillary thyroid carcinoma to poorly differentiated thyroid carcinoma and overt undifferentiated anaplastic thyroid carcinoma with highly pleomorphic, atypical cells with evidence of necrosis
• carcinoma in tamoxifen treated mice shows tracheal invasion and extrathyroidal extension
• marker analysis indicates that anaplastic thyroid carcinoma in tamoxifen treated mice originates from thyroid epithelium
• tumors from tamoxifen treated mice exhibit very slow initial growth upon induction but rapid tumor growth after a variable latency
• mice supplemented with L-thyroxine immediately following tamoxifen administration show suppressed TSH levels and develop anaplastic thyroid carcinoma with a similar latency as unsupplemented controls
• anaplastic thyroid carcinomas exhibit a gene expression profile of high-grade, undifferentiated carcinomas
• tumor induced mice treated with the BRAF inhibitor PLX4720 show improved survival and a decrease in contralateral papillary thyroid carcinomas, however no decrease in anaplastic thyroid carcinoma size is seen and tumors even grow larger
• tumor induced mice treated with both the BRAF inhibitor PLX4720 and the selective MEK inhibitor PD0325901 show complete regression of tumors and prolonged survival

homeostasis/metabolism
increased thyroid-stimulating hormone level ( J:208854 )
• small increase in TSH levels (less than 10-fold elevation) in tamoxifen treated mice
• mice supplemented with L-thyroxine immediately following tamoxifen administration show suppressed TSH levels

respiratory system
respiratory failure ( J:208854 )
• tamoxifen treated mice quickly deteriorate after progression to anaplastic thyroid carcinoma, with rapidly growing neck masses and development of audible respiratory stridor




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
12/10/2024
MGI 6.24 		The Jackson Laboratory